Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (specifically alpha-tocopheryl acetate) has been investigated for its potential to reduce certain side effects of chemotherapy, particularly chemotherapy-induced peripheral neuropathy (CIPN). Several small randomized controlled trials and meta-analyses have examined whether Vitamin E supplementation can prevent or attenuate neurotoxicity caused by agents such as cisplatin, paclitaxel, and oxaliplatin. Some studies observed a reduction in the incidence or severity of neuropathy symptoms in patients taking Vitamin E, with dosages commonly in the range of 300-600 mg per day. For example, a 2017 meta-analysis (Supportive Care in Cancer) concluded that Vitamin E might have a protective effect against CIPN, although the included studies were small and heterogeneous.

However, the evidence is inconsistent, and some well-designed studies have found no benefit. Furthermore, concerns have been raised regarding the potential interference of antioxidants with the efficacy of chemotherapy, based on theoretical risks that antioxidants could protect tumor cells as well as healthy tissue. Major guidelines (such as those from ASCO and ESMO) do not recommend routine use of Vitamin E for this purpose, citing insufficient and conflicting evidence. Therefore, while there is some scientific rationale and preliminary evidence, the overall quality and consistency of studies are limited, resulting in a low to moderate evidence rating.

More about Vitamin E (alpha tocopheryl acetate)
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Vitamin E (alpha tocopheryl acetate)

Products containing Vitamin E (alpha tocopheryl acetate)